Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 486

1.

Quantification of microplastic ingestion by the decapod crustacean Nephrops norvegicus from Irish waters.

Hara J, Frias J, Nash R.

Mar Pollut Bull. 2020 Jan 15;152:110905. doi: 10.1016/j.marpolbul.2020.110905. [Epub ahead of print]

PMID:
31957681
2.

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.

McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, Lingvay I.

Diabetologia. 2020 Jan 2. doi: 10.1007/s00125-019-05065-8. [Epub ahead of print]

PMID:
31897524
3.

The SYDNEY Device Study: A Multicenter, Randomized, Open-Label Usability Study of a 2-mL Alirocumab Autoinjector Device.

Frias JP, Koren MJ, Loizeau V, Merino-Trigo A, Louie MJ, Raudenbush MA, Batsu I.

Clin Ther. 2019 Dec 23. pii: S0149-2918(19)30569-7. doi: 10.1016/j.clinthera.2019.11.008. [Epub ahead of print]

4.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE.

Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.

PMID:
31727409
5.

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.

Pettus JH, D'Alessio D, Frias JP, Vajda EG, Pipkin JD, Rosenstock J, Williamson G, Zangmeister MA, Zhi L, Marschke KB.

Diabetes Care. 2020 Jan;43(1):161-168. doi: 10.2337/dc19-1328. Epub 2019 Nov 6.

PMID:
31694861
6.

Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.

Desouza CV, Holcomb RG, Rosenstock J, Frias JP, Hsia SH, Klein EJ, Zhou R, Kohzuma T, Fonseca VA.

J Clin Endocrinol Metab. 2019 Oct 25. pii: dgz087. doi: 10.1210/clinem/dgz087. [Epub ahead of print]

PMID:
31650161
7.

Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.

Aroda VR, Capehorn MS, Chaykin L, Frias JP, Lausvig NL, Macura S, Lüdemann J, Madsbad S, Rosenstock J, Tabak O, Tadayon S, Bain SC.

Diabetes Obes Metab. 2019 Oct 13. doi: 10.1111/dom.13896. [Epub ahead of print]

PMID:
31608552
8.

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.

Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ.

Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17.

PMID:
31540867
9.

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR.

Diabetes Care. 2019 Nov;42(11):2108-2116. doi: 10.2337/dc19-1357. Epub 2019 Sep 17.

PMID:
31530665
10.

Seed Protein of Lentils: Current Status, Progress, and Food Applications.

Khazaei H, Subedi M, Nickerson M, Martínez-Villaluenga C, Frias J, Vandenberg A.

Foods. 2019 Sep 4;8(9). pii: E391. doi: 10.3390/foods8090391. Review.

11.

Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.

Ferrannini E, Baldi S, Frías JP, Guja C, Hardy E, Repetto E, Jabbour SA, DeFronzo RA.

Diabetes Obes Metab. 2020 Jan;22(1):99-106. doi: 10.1111/dom.13870. Epub 2019 Oct 8.

PMID:
31469220
12.

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

Davidson JA, Desouza C, Fonseca V, Frias JP, Van Gaal L, Giorgino F, Chao J, Dex TA, Roberts M, Saremi A, Leiter LA.

Diabet Med. 2019 Jul 31. doi: 10.1111/dme.14094. [Epub ahead of print]

PMID:
31365765
13.

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Blonde L, Bailey TS, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M, Aroda VR.

Adv Ther. 2019 Sep;36(9):2310-2326. doi: 10.1007/s12325-019-01033-1. Epub 2019 Jul 29.

14.

The Statistical Optimisation of Recombinant β-glucosidase Production through a Two-Stage, Multi-Model, Design of Experiments Approach.

Uhoraningoga A, Kinsella GK, Frias JM, Henehan GT, Ryan BJ.

Bioengineering (Basel). 2019 Jul 18;6(3). pii: E61. doi: 10.3390/bioengineering6030061.

15.

Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.

Dapía I, García I, Martinez JC, Arias P, Guerra P, Díaz L, García A, Ochoa D, Tenorio J, Ramírez E, Román M, Gordo G, Saiz-Rodríguez M, Frías J, Abad-Santos F, Lapunzina P, Carcas AJ, Borobia AM.

Int J Antimicrob Agents. 2019 Oct;54(4):463-470. doi: 10.1016/j.ijantimicag.2019.06.026. Epub 2019 Jul 4.

PMID:
31279853
16.

Severe Hyponatremia Is Often Drug Induced: 10-Year Results of a Prospective Pharmacovigilance Program.

Ramírez E, Rodríguez A, Queiruga J, García I, Díaz L, Martínez L, Muñoz R, Muñoz M, Tong HY, Martínez JC, Borobia AM, Carcas AJ, Frías J.

Clin Pharmacol Ther. 2019 Dec;106(6):1362-1379. doi: 10.1002/cpt.1562. Epub 2019 Sep 10.

PMID:
31247118
17.

Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal.

Vargas-Uricoechea H, Frias JP.

Diabetes Metab Syndr. 2019 May - Jun;13(3):1975-1989. doi: 10.1016/j.dsx.2019.04.014. Epub 2019 Apr 25. Review. No abstract available.

PMID:
31235124
18.

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.

Sullivan SD, Nicholls CJ, Gupta RA, Menon AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS.

Diabetes Obes Metab. 2019 Sep;21(9):2123-2132. doi: 10.1111/dom.13793. Epub 2019 Jun 21.

19.

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.

Frias JP, Wynne AG, Matyjaszek-Matuszek B, Bartaskova D, Cox DA, Woodward B, Li YG, Tham LS, Milicevic Z.

Diabetes Obes Metab. 2019 Sep;21(9):2048-2057. doi: 10.1111/dom.13764. Epub 2019 Jun 3.

PMID:
31050143
20.

Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.

Pérez C, Mondéjar R, García-Díaz N, Cereceda L, León A, Montes S, Durán Vian C, Pérez Paredes MG, González-Morán A, Alegre de Miguel V, Sanz Anquela JM, Frias J, Limeres MA, González LM, Martín Dávila F, Beltrán M, Mollejo M, Méndez JR, González MA, González García J, López R, Gómez A, Izquierdo F, Ramos R, Camacho C, Rodriguez-Pinilla SM, Martínez N, Vaqué JP, Ortiz-Romero PL, Piris MA.

Br J Dermatol. 2020 Jan;182(1):147-155. doi: 10.1111/bjd.18098. Epub 2019 Jul 25.

PMID:
31049933
21.

Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.

Bergenstal RM, Peyrot M, Dreon DM, Aroda VR, Bailey TS, Brazg RL, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Ramtoola S, Rosenstock J, Serusclat P, Weinstock RS, Naik RG, Shearer DM, Zraick V, Levy BL; Calibra Study Group.

Diabetes Technol Ther. 2019 May;21(5):273-285. doi: 10.1089/dia.2018.0298. Epub 2019 Apr 26.

22.

Nutraceutical formulation, characterisation, and in-vitro evaluation of methylselenocysteine and selenocystine using food derived chitosan:zein nanoparticles.

Vozza G, Khalid M, Byrne HJ, Ryan SM, Frias JM.

Food Res Int. 2019 Jun;120:295-304. doi: 10.1016/j.foodres.2019.02.028. Epub 2019 Feb 19.

PMID:
31000242
23.

Prioritising injectable therapies in the management of type 2 diabetes.

Frias JP.

Lancet Diabetes Endocrinol. 2019 Jul;7(7):505-508. doi: 10.1016/S2213-8587(19)30117-2. Epub 2019 Apr 10. No abstract available.

PMID:
30981766
24.

Correction to: Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.

Martínez-Ávila JC, García Bartolomé A, García I, Dapía I, Tong HY, Díaz L, Guerra P, Frías J, Carcás Sansuan AJ, Borobia AM.

Metabolomics. 2018 Jun 14;14(6):87. doi: 10.1007/s11306-018-1378-0.

PMID:
30834989
25.

Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.

Martínez-Ávila JC, García Bartolomé A, García I, Dapía I, Tong HY, Díaz L, Guerra P, Frías J, Carcás Sansuan AJ, Borobia AM.

Metabolomics. 2018 May 9;14(5):70. doi: 10.1007/s11306-018-1365-5. Erratum in: Metabolomics. 2018 Jun 14;14(6):87.

PMID:
30830352
26.

Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.

Frias JP.

Expert Rev Endocrinol Metab. 2019 Mar;14(2):75-83. doi: 10.1080/17446651.2019.1571908. Epub 2019 Feb 5.

PMID:
30724637
27.

Microplastics: Finding a consensus on the definition.

Frias JPGL, Nash R.

Mar Pollut Bull. 2019 Jan;138:145-147. doi: 10.1016/j.marpolbul.2018.11.022. Epub 2018 Nov 22.

PMID:
30660255
28.

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.

Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, O'Neill EA, Engel SS, Kaufman KD, Makimura H, Crutchlow MF.

Diabetes Obes Metab. 2019 May;21(5):1128-1135. doi: 10.1111/dom.13626. Epub 2019 Feb 17.

29.

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.

Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP.

J Diabetes Complications. 2019 Mar;33(3):236-242. doi: 10.1016/j.jdiacomp.2018.11.009. Epub 2018 Nov 30.

30.

Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.

Schmider W, Belder R, Lee M, Niemoeller E, Souhami E, Frias JP.

Curr Med Res Opin. 2019 Jun;35(6):1081-1089. doi: 10.1080/03007995.2018.1558852. Epub 2019 Jan 11.

PMID:
30550345
31.

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.

Frias JP, Dex T, Roberts M, Kaplan A.

Diabetes Ther. 2019 Feb;10(1):21-33. doi: 10.1007/s13300-018-0547-5. Epub 2018 Dec 11. Review.

32.

Two unrelated patients with autosomal dominant omodysplasia and FRIZZLED2 mutations.

Warren HE, Louie RJ, Friez MJ, Frías JL, Leroy JG, Spranger JW, Skinner SA, Champaigne NL.

Clin Case Rep. 2018 Oct 15;6(11):2252-2255. doi: 10.1002/ccr3.1818. eCollection 2018 Nov.

33.

Pilot-scale produced fermented lentil protects against t-BHP-triggered oxidative stress by activation of Nrf2 dependent on SAPK/JNK phosphorylation.

Bautista-Expósito S, Peñas E, Frias J, Martínez-Villaluenga C.

Food Chem. 2019 Feb 15;274:750-759. doi: 10.1016/j.foodchem.2018.09.012. Epub 2018 Sep 3.

PMID:
30373004
34.

Microplastics in Galway Bay: A comparison of sampling and separation methods.

Pagter E, Frias J, Nash R.

Mar Pollut Bull. 2018 Oct;135:932-940. doi: 10.1016/j.marpolbul.2018.08.013. Epub 2018 Aug 16.

PMID:
30301118
35.

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.

Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4.

PMID:
30293770
36.

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.

Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M.

PLoS One. 2018 Sep 25;13(9):e0203946. doi: 10.1371/journal.pone.0203946. eCollection 2018.

37.

Effectiveness and limitations of an incident-reporting system analyzed by local clinical safety leaders in a tertiary hospital: Prospective evaluation through real-time observations of patient safety incidents.

Ramírez E, Martín A, Villán Y, Lorente M, Ojeda J, Moro M, Vara C, Avenza M, Domingo MJ, Alonso P, Asensio MJ, Blázquez JA, Hernández R, Frías J, Frank A; SINOIRES Working Group.

Medicine (Baltimore). 2018 Sep;97(38):e12509. doi: 10.1097/MD.0000000000012509.

38.

Application of Box-Behnken experimental design for the formulation and optimisation of selenomethionine-loaded chitosan nanoparticles coated with zein for oral delivery.

Vozza G, Danish M, Byrne HJ, Frías JM, Ryan SM.

Int J Pharm. 2018 Nov 15;551(1-2):257-269. doi: 10.1016/j.ijpharm.2018.08.050. Epub 2018 Aug 25.

PMID:
30153488
39.

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.

Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB.

Diabetes Care. 2018 Oct;41(10):2147-2154. doi: 10.2337/dc18-0559. Epub 2018 Aug 13.

PMID:
30104294
40.

Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.

Parker ED, Wittbrodt ET, McPheeters JT, Frias JP.

Diabetes Obes Metab. 2019 Feb;21(2):227-233. doi: 10.1111/dom.13502. Epub 2018 Sep 10.

PMID:
30101553
42.

Spatio-temporal variability of beached macro-litter on remote islands of the North Atlantic.

Ríos N, Frias JPGL, Rodríguez Y, Carriço R, Garcia SM, Juliano M, Pham CK.

Mar Pollut Bull. 2018 Aug;133:304-311. doi: 10.1016/j.marpolbul.2018.05.038. Epub 2018 Jun 19.

PMID:
30041319
43.

The transcription factor Tfap2e/AP-2ε plays a pivotal role in maintaining the identity of basal vomeronasal sensory neurons.

Lin JM, Taroc EZM, Frias JA, Prasad A, Catizone AN, Sammons MA, Forni PE.

Dev Biol. 2018 Sep 1;441(1):67-82. doi: 10.1016/j.ydbio.2018.06.007. Epub 2018 Jun 19.

44.
45.

Microplastics on the Portuguese coast.

Antunes J, Frias J, Sobral P.

Mar Pollut Bull. 2018 Jun;131(Pt A):294-302. doi: 10.1016/j.marpolbul.2018.04.025. Epub 2018 May 7.

PMID:
29886950
46.

More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.

Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR.

Diabetes Obes Metab. 2018 Sep;20(9):2314-2318. doi: 10.1111/dom.13368. Epub 2018 Jun 13.

47.

Biologics and Cardiovascular Disease.

Van Taunay JS, Albelda MT, Frias JC, Lipinski MJ.

J Cardiovasc Pharmacol. 2018 Aug;72(2):77-85. doi: 10.1097/FJC.0000000000000595. Review.

PMID:
29738370
48.

Sodium caprate enables the blood pressure-lowering effect of Ile-Pro-Pro and Leu-Lys-Pro in spontaneously hypertensive rats by indirectly overcoming PepT1 inhibition.

Gleeson JP, Frías JM, Ryan SM, Brayden DJ.

Eur J Pharm Biopharm. 2018 Jul;128:179-187. doi: 10.1016/j.ejpb.2018.04.021. Epub 2018 Apr 20.

PMID:
29684535
49.

Individual contributions of Savinase and Lactobacillus plantarum to lentil functionalization during alkaline pH-controlled fermentation.

Bautista-Expósito S, Peñas E, Dueñas M, Silván JM, Frias J, Martínez-Villaluenga C.

Food Chem. 2018 Aug 15;257:341-349. doi: 10.1016/j.foodchem.2018.03.044. Epub 2018 Mar 12.

PMID:
29622220
50.

Supplemental Content

Support Center